Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Smit

Showing results (851-860 of 881) with videos related to

Pageof 89
Sort By:
The Lancet. Oncology|February 17, 2018
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
Endocrine-Related Cancer|July 25, 2019
The molecular genetic make-up of male breast cancerCathy B Moelans, Joep de Ligt, Petra van der Groep, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control studyMarleen A E van der Kaaij, Natacha Heutte, Paul Meijnders, et al.
European Journal of Haematology|February 17, 2025
Treatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML PatientsC Kockerols, P J M Valk, P Hogenbirk, et al.
The New England Journal of Medicine|June 13, 2003
Involved-field radiotherapy for advanced Hodgkin's lymphomaBerthe M P Aleman, John M M Raemaekers, Umberto Tirelli, et al.
Nature Communications|November 24, 2021
Adaptation, spread and transmission of SARS-CoV-2 in farmed minks and associated humans in the NetherlandsLu Lu, Reina S Sikkema, Francisca C Velkers, et al.
The Lancet. Oncology|July 27, 2019
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
Human Reproduction (Oxford, England)|December 19, 2013
Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort studyM A E van der Kaaij, J van Echten-Arends, N Heutte, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 1, 2026
Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer - PORTEC-4a an international, randomised, phase 3 trialAnne Sophie V M van den Heerik, Nanda Horeweg, Marie A D Haverkort, et al.
Pageof 89

Showing results (851-860 of 881) with videos related to

Sort By:
Pageof 89
The Lancet. Oncology|February 17, 2018
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
Endocrine-Related Cancer|July 25, 2019
The molecular genetic make-up of male breast cancerCathy B Moelans, Joep de Ligt, Petra van der Groep, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control studyMarleen A E van der Kaaij, Natacha Heutte, Paul Meijnders, et al.
European Journal of Haematology|February 17, 2025
Treatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML PatientsC Kockerols, P J M Valk, P Hogenbirk, et al.
The New England Journal of Medicine|June 13, 2003
Involved-field radiotherapy for advanced Hodgkin's lymphomaBerthe M P Aleman, John M M Raemaekers, Umberto Tirelli, et al.
Nature Communications|November 24, 2021
Adaptation, spread and transmission of SARS-CoV-2 in farmed minks and associated humans in the NetherlandsLu Lu, Reina S Sikkema, Francisca C Velkers, et al.
The Lancet. Oncology|July 27, 2019
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trialStephanie M de Boer, Melanie E Powell, Linda Mileshkin, et al.
Human Reproduction (Oxford, England)|December 19, 2013
Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort studyM A E van der Kaaij, J van Echten-Arends, N Heutte, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 1, 2026
Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer - PORTEC-4a an international, randomised, phase 3 trialAnne Sophie V M van den Heerik, Nanda Horeweg, Marie A D Haverkort, et al.
Pageof 89